Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270744 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL2270739 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL28361607 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL7774457 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL7774459 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL7774454 | 1.00 | TLR4 (0.35) | TLR4CYP1A2CYP2C9 | |
| SCHEMBL7909879 | 0.94 | CYP1A2 (0.36) | TLR4CYP1A2 | |
| SCHEMBL7909890 | 0.94 | CYP1A2 (0.36) | TLR4CYP1A2 | |
| SCHEMBL7909881 | 0.94 | CYP1A2 (0.36) | TLR4CYP1A2 | |
| SCHEMBL8725666 | 0.94 | CYP1A2 (0.34) | CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283460-A | Synthesis method of trans-4- (trans-4' -alkyl cyclohexyl) cyclohexyl ethylene liquid crystal monomer | 山东盛华新材料科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-107963958-B | Synthesis method of trans-4- (trans-4' -alkylcyclohexyl) cyclohexyl ethylene liquid crystal monomer | 西安瑞联新材料股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
| US-5348677-A | Electro-optical liquid crystal display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-09-20 | — | — | US | disclosed |
| US-5318721-A | Nematic liquid-crystalline phases | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-06-07 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| EP-0313604-B1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| EP-0264435-B1 | SMECTIC LIQUID CRYSTAL PHASES | MERCK PATENT GmbH (DE) | 1992-03-04 | — | — | EP | disclosed |
| US-4871469-A | TRIFLUOROTOLUENE DERIVATIVES | BESCRANKTER HAFTUNG (DE) | 1989-10-03 | — | — | US | disclosed |
| EP-0313604-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT. | MERCK PATENT GMBH (DE) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988008441-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-11-03 | — | — | WO | disclosed |
| EP-0264435-A1 | SMECTIC LIQUID CRYSTAL PHASES. | MERCK PATENT GMBH (DE) | 1988-04-27 | — | — | EP | disclosed |
| WO-1987006602-A1 | SMECTIC LIQUID CRYSTAL PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | TLR4 2044/4885CYP1A2 40/4885CYP2C9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.